You want to charge $1M for that gene ther­a­py? Here’s where you’re wrong

Spark Ther­a­peu­tics $ONCE doesn’t have a green light yet from the FDA to sell its gene ther­a­py for one small group of pa­tients with a ge­net­ic flaw that caus­es in­her­it­ed blind­ness. And com­pa­ny ex­ecs haven’t told any­one ex­act­ly what its whole­sale price will be for voreti­gene nepar­vovec.

But the odds look great for this treat­ment to quick­ly nab the first ap­proval for a vec­tor-de­liv­ered gene ther­a­py in the US — and it’s game on for a pric­ing de­bate that starts with an auc­tion fore­cast of $1 mil­lion per treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER